The net income of China Life in the first quarter was 20.64 billion yuan.
This represents a decrease of 9.3% year on year, a drop from 22.77 billion yuan reported in the same timeframe the previous year.
The operating income for this period, however, saw an increase, rising 14% year on year to a total of 120.97 billion yuan.
Analysts’ opinions on China Life are largely positive, with the company receiving 22 ‘buy’ evaluations, one ‘hold’ and two ‘sell’ evaluations.
The data used for comparisons to past results was reported directly by the company in its original disclosures.
A look at China Life Insurance Co H Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have given China Life Insurance Co H a strong overall outlook based on their Smart Scores. With top scores in Value and Dividend, the company is considered well-positioned in terms of financial stability and investor returns. Additionally, its impressive Momentum score indicates positive market sentiment and potential for growth. Although the company scored slightly lower in Growth and Resilience, it remains a solid choice for investors seeking long-term stability and consistent dividends.
China Life Insurance Company Ltd. is a leading provider of life, accident, and health insurance products and services. With high scores in Value and Dividend, investors can expect solid financial performance and attractive returns. The company’s strong Momentum score suggests positive market trends and future growth potential. While its Growth and Resilience scores are slightly lower, China Life Insurance Co H remains a fundamentally sound choice for those looking to invest in a reliable and established insurance company.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
